Related Experiment Videos
Low molecular weight heparins: current use and indications
M A Quader1, L S Stump, B E Sumpio
1Department of Surgery, Yale University School of Medicine, New Haven, CT 06510, USA.
Journal of the American College of Surgeons
|December 16, 1998
Summary
Low molecular weight heparins (LMWHs) offer improved safety and efficacy for preventing and treating thromboembolic events compared to unfractionated heparin. LMWHs are cost-effective and enable outpatient treatment, improving patient outcomes and reducing healthcare costs.
Area of Science:
- Pharmacology
- Cardiovascular Medicine
- Hematology
Background:
- Thromboembolic complications pose significant risks in postoperative patients.
- Unfractionated heparin has been the standard for prophylaxis, but newer agents are emerging.
Purpose of the Study:
- To evaluate the safety and efficacy of low molecular weight heparins (LMWHs) in managing thromboembolic diseases.
- To compare LMWHs with unfractionated heparin and warfarin in various clinical settings.
Main Methods:
- Review of clinical trials and comparative studies.
- Analysis of efficacy, safety, administration, and cost-effectiveness data.
Main Results:
- LMWHs demonstrate equipotent or superior efficacy to unfractionated heparin and warfarin.
- LMWHs are particularly effective in orthopedic surgery prophylaxis, unstable angina, and trauma.
- LMWHs offer advantages in ease of administration and reduced monitoring needs, with similar or lower overall costs.
Conclusions:
- LMWHs are a safe and effective alternative to unfractionated heparin and warfarin for thromboembolic disease management.
- LMWHs facilitate outpatient treatment, improving patient convenience and potentially reducing healthcare expenditures.
- Further research is needed to establish the role of LMWHs in specific conditions like ischemic heart disease and valvular heart disease.